Michael de Graaf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael de Graaf has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
André Gerardus Uitterlinden
Erasmus Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands
1 shared publicationAnnemieke Johanna Maria Henriëtta Verkerk
Erasmus Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands
1 shared publicationEgbert Johan Willem Redeker
Academic Medical Center, Department of Clinical Genetics, Amsterdam, The Netherlands
1 shared publicationGijs Willem Eduard Santen
Leiden University Medical Center, Department of Clinical Genetics, Leiden, The Netherlands
1 shared publicationJan Maarten Wit
Leiden University Medical Center, Department of Pediatrics, Leiden, the Netherlands
1 shared publicationMonique Losekoot
Leiden University Medical Center, Department of Clinical Genetics, Leiden, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 14 December 2017
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 9 (4) , 366-370
Successful Growth Hormone Therapy in Cornelia de Lange Syndrome
Cornelia de Lange syndrome (CdLS) is a both clinically and genetically heterogeneous syndrome. In its classical form, it is characterised by distinctive facial features, intra-uterine growth retardation, short stature, developmental delay, and anomalies in multiple organ systems. NIPBL, SMC1A, SMC3, RAD21 and HDAC8, all involved in the cohesin pathway, have been identified to cause CdLS. Growth hormone (GH) secretion has been reported as normal, and to our knowledge, there are no reports on the effect of recombinant human GH treatment in CdLS patients. We present a patient born small for gestational age with persistent severe growth retardation [height -3.4 standard deviation score (SDS)] and mild dysmorphic features, who was treated with GH from 4.3 years of age onward and was diagnosed 6 years later with CdLS using whole-exome sequencing. Treatment led to a height gain of 1.6 SDS over 8 years. Treatment was interrupted shortly due to high serum insulin-like growth factor-1 serum values. In conclusion, GH therapy may be effective and safe for short children with CdLS.
- 14 December 2017
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 9 (4) , 366-370
Open AccessSuccessful Growth Hormone Therapy in Cornelia de Lange Syndrome
Cornelia de Lange syndrome (CdLS) is a both clinically and genetically heterogeneous syndrome. In its classical form, it is characterised by distinctive facial features, intra-uterine growth retardation, short stature, developmental delay, and anomalies in multiple organ systems. NIPBL, SMC1A, SMC3, RAD21 and HDAC8, all involved in the cohesin pathway, have been identified to cause CdLS. Growth hormone (GH) secretion has been reported as normal, and to our knowledge, there are no reports on the effect of recombinant human GH treatment in CdLS patients. We present a patient born small for gestational age with persistent severe growth retardation [height -3.4 standard deviation score (SDS)] and mild dysmorphic features, who was treated with GH from 4.3 years of age onward and was diagnosed 6 years later with CdLS using whole-exome sequencing. Treatment led to a height gain of 1.6 SDS over 8 years. Treatment was interrupted shortly due to high serum insulin-like growth factor-1 serum values. In conclusion, GH therapy may be effective and safe for short children with CdLS.